First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC

Cemiplimab plus ipilimumab for advanced NSCLC

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer

Highlights from AORTIC Cancer Genomics Conference 2021

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

The Conquering Cancer Campaign

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy

ecancer special issue on medical education in Africa

Demographic, clinical and pathological characterisation of patients with colorectal and anal cancer in Mozambique

Cancer Genomics in Africa today